» Articles » PMID: 22244884

Management of Recurrent Cervical Cancer: a Review of the Literature

Overview
Journal Surg Oncol
Date 2012 Jan 17
PMID 22244884
Citations 85
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The aim of this narrative review is to update the current knowledge on the treatment of recurrent cervical cancer based on a literature review.

Material And Methods: A web based search in Medline and CancerLit databases has been carried out on recurrent cervical cancer management and treatment. All relevant information has been collected and analyzed, prioritizing randomized clinical trials.

Results: Cervical cancer still represents a significant problem for public health with an annual incidence of about half a million new cases worldwide. Percentages of pelvic recurrences fluctuate from 10% to 74% depending on different risk factors. Accordingly to the literature, it is suggested that chemoradiation treatment (containing cisplatin and/or taxanes) could represent the treatment of choice for locoregional recurrences of cervical cancer after radical surgery. Pelvic exenteration is usually indicated for selected cases of central recurrence of cervical cancer after primary or adjuvant radiation and chemotherapy with bladder and/or rectum infiltration neither extended to the pelvic side walls nor showing any signs of extrapelvic spread of disease. Laterally extended endopelvic resection (LEER) for the treatment of those patients with a locally advanced disease or with a recurrence affecting the pelvic wall has been described.

Conclusions: The treatment of recurrences of cervical carcinoma consists of surgery, and of radiation and chemotherapy, or the combination of different modalities taking into consideration the type of primary therapy, the site of recurrence, the disease-free interval, the patient symptoms, performance status, and the degree to which any given treatment might be beneficial.

Citing Articles

PET CT Imaging with FDG in the Therapeutical Management of Locally Advanced Cervical Cancer Diagnosed in a 43-Year-Old Patient: Case Report and Review of the Literature.

Molnar O, Mihutiu S, Straciuc O, Vesa A, Lazar L Biomedicines. 2025; 13(1).

PMID: 39857668 PMC: 11760832. DOI: 10.3390/biomedicines13010083.


Predicting High-Grade Acute Urinary Toxicity and Lower Gastrointestinal Toxicity After Postoperative Volumetric Modulated Arc Therapy for Cervical and Endometrial Cancer Using a Normal Tissue Complication Probability Model.

Yang T, Ji Z, Lei R, Qu A, Jiang W, Deng X Curr Oncol. 2025; 32(1.

PMID: 39851942 PMC: 11763444. DOI: 10.3390/curroncol32010026.


Decoding the influence of external beam radiotherapy to brachytherapy duration and overall treatment on response and early recurrences in cervical cancer patients treated with chemoradiation.

Krishna A, Makkapatti B, Athiyamaan M, Lobo D, Srinivas C, Sunny J Radiat Oncol J. 2025; 42(4):257-262.

PMID: 39748526 PMC: 11701466. DOI: 10.3857/roj.2023.01025.


Bidirectional recurrent neural network approach for predicting cervical cancer recurrence and survival.

Geeitha S, Prabha K, Cho J, Veerappampalayam Easwaramoorthy S Sci Rep. 2024; 14(1):31641.

PMID: 39738223 PMC: 11685496. DOI: 10.1038/s41598-024-80472-5.


Prognostic significance of systemic pan-immune-inflammation value in locally advanced cervical cancer.

Yan S, Gong X, Liu R, Jia X Front Oncol. 2024; 14:1492251.

PMID: 39529824 PMC: 11551031. DOI: 10.3389/fonc.2024.1492251.